{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:47:35Z","timestamp":1787986055085,"version":"build-2784847793"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T00:00:00Z","timestamp":1513728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["109130\/Z\/15\/Z"],"award-info":[{"award-number":["109130\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["201251\/Z\/16\/Z"],"award-info":[{"award-number":["201251\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI069481"],"award-info":[{"award-number":["AI069481"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI-27757"],"award-info":[{"award-number":["AI-27757"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI068636"],"award-info":[{"award-number":["AI068636"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.1093\/cid\/cix1108","type":"journal-article","created":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T12:08:17Z","timestamp":1513598897000},"page":"1846-1857","source":"Crossref","is-referenced-by-count":62,"title":["Effectiveness of Protease Inhibitor\/Nucleos(t)ide Reverse Transcriptase Inhibitor\u2013Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis"],"prefix":"10.1093","volume":"66","author":[{"given":"Alexander J","family":"Stockdale","sequence":"first","affiliation":[{"name":"Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre"},{"name":"Institute of Infection and Global Health, University of Liverpool"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J","family":"Saunders","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases and Immunity and Wellcome Trust\u2013Imperial College Centre for Global Health Research, Imperial College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Boyd","sequence":"additional","affiliation":[{"name":"Kirby Institute for Infection and Immunity, University of New South Wales, Sydney"},{"name":"Lyell McEwin Hospital, University of Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J","family":"Bonnett","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Liverpool"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Johnston","sequence":"additional","affiliation":[{"name":"London School of Hygiene and Tropical Medicine, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Wandeler","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventative Medicine, University of Bern"},{"name":"Department of Infectious Diseases, Bern University Hospital, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelot F","family":"Schoffelen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University Medical Centre Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ciaffi","sequence":"additional","affiliation":[{"name":"Unit\u00e9 Mixte de Recherche de l\u2019Institut de Rech (UMI), Institute de Recherche pour le D\u00e9veloppement, Institute National de la Sant\u00e9 et de la Recherche Medicale, University of Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Stafford","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann C","family":"Collier","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas I","family":"Paton","sequence":"additional","affiliation":[{"name":"Yong Loo Lin School of Medicine, National University of Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Geretti","sequence":"additional","affiliation":[{"name":"Institute of Infection and Global Health, University of Liverpool"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,12,20]]},"reference":[{"key":"key\n\t\t\t\t20180626050757_CIT0001","volume-title":"Global AIDS update. Geneva, Switzerland: UNAIDS","author":"Joint United Nations Programme on HIV\/AIDS","year":"2016"},{"key":"key\n\t\t\t\t20180626050757_CIT0002","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1126\/science.1230413","article-title":"Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment","volume":"339","author":"Bor","year":"2013","journal-title":"Science"},{"key":"key\n\t\t\t\t20180626050757_CIT0003","volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection","author":"World Health Organization","year":"2016"},{"key":"key\n\t\t\t\t20180626050757_CIT0004","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3018(17)30109-1","article-title":"Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV\/AIDS: a systematic review and network meta-analysis","volume":"4","author":"Kanters","year":"2017","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180626050757_CIT0005","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2352-3018(14)00061-7","article-title":"Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis","volume":"2","author":"Boyd","year":"2015","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180626050757_CIT0006","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2352-3018(17)30065-6","article-title":"Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial","volume":"4","author":"Paton","year":"2017","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180626050757_CIT0007","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1016\/S2352-3018(15)00087-9","article-title":"Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis","volume":"2","author":"Haas","year":"2015","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180626050757_CIT0008","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3018(16)00016-3","article-title":"The need for second-line antiretroviral therapy in adults in sub-Saharan Africa up to 2030: a mathematical modelling study","volume":"3","author":"Estill","year":"2016","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180626050757_CIT0009","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180626050757_CIT0010","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180626050757_CIT0011","author":"Higgins"},{"key":"key\n\t\t\t\t20180626050757_CIT0012","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180626050757_CIT0013","doi-asserted-by":"crossref","first-page":"e0118228","DOI":"10.1371\/journal.pone.0118228","article-title":"Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir\/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection","volume":"10","author":"Amin","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180626050757_CIT0014","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/S0140-6736(13)61164-2","article-title":"Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study","volume":"381","author":"Boyd","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180626050757_CIT0015","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/QAD.0000000000000709","article-title":"Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa","volume":"29","author":"Ciaffi","year":"2015","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180626050757_CIT0016","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3018(14)00007-1","article-title":"Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial","volume":"2","author":"Gross","year":"2015","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180626050757_CIT0017","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/S2352-3018(16)30011-X","article-title":"Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study","volume":"3","author":"La Rosa","year":"2016","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180626050757_CIT0018","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1056\/NEJMoa1311274","article-title":"Assessment of second-line antiretroviral regimens for HIV therapy in Africa","volume":"371","author":"Paton","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180626050757_CIT0019","article-title":"Favorable long-term outcomes of 2nd-line ART despite drug-resistant HIV-1 in sub-Saharan Africa","volume":"22","author":"Boender","year":"2014","journal-title":"Top Antivir Med"},{"key":"key\n\t\t\t\t20180626050757_CIT0020","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/1545109708328538","article-title":"Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity","volume":"8","author":"Castelnuovo","year":"2009","journal-title":"J Int Assoc Physicians AIDS Care (Chic)"},{"key":"key\n\t\t\t\t20180626050757_CIT0021","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1468-1293.2010.00825.x","article-title":"Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline","volume":"11","author":"Hosseinipour","year":"2010","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20180626050757_CIT0022","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/2325957414527167","article-title":"Long-term outcome of second-line antiretroviral therapy in resource-limited settings","volume":"13","author":"Osinusi-Adekanmbi","year":"2014","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"key\n\t\t\t\t20180626050757_CIT0023","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/infdis\/jis261","article-title":"Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in sub-Saharan Africa","volume":"205","author":"Sigaloff","year":"2012","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180626050757_CIT0024","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/QAI.0b013e3182632540","article-title":"Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies","volume":"61","author":"Wandeler","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180626050757_CIT0025","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/infdis\/jiw219","article-title":"Protease inhibitor resistance in the first 3 years of second-line antiretroviral therapy for HIV-1 in sub-Saharan Africa","volume":"214","author":"Boender","year":"2016","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180626050757_CIT0026","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/1545109712463733","article-title":"Optimizing treatment switch for virologic failure during first-line antiretroviral therapy in resource-limited settings","volume":"12","author":"Adetunji","year":"2013","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"key\n\t\t\t\t20180626050757_CIT0027","doi-asserted-by":"crossref","first-page":"e36997","DOI":"10.1371\/journal.pone.0036997","article-title":"Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome","volume":"7","author":"Johnston","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180626050757_CIT0028","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/QAI.0b013e3182615ad1","article-title":"Second-line antiretroviral therapy: long-term outcomes in South Africa","volume":"61","author":"Murphy","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180626050757_CIT0029","doi-asserted-by":"crossref","first-page":"e58526","DOI":"10.1371\/journal.pone.0058526","article-title":"Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa","volume":"8","author":"Schoffelen","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180626050757_CIT0030","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/infdis\/jit411","article-title":"Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch","volume":"209","author":"Johnston","year":"2014","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180626050757_CIT0031","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/tmi.12804","article-title":"Treatment outcomes of over 1000 patients on second-line, protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa","volume":"22","author":"Shearer","year":"2017","journal-title":"Trop Med Int Health"},{"key":"key\n\t\t\t\t20180626050757_CIT0032","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijantimicag.2016.04.030","article-title":"Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy","volume":"48","author":"Court","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180626050757_CIT0033","doi-asserted-by":"crossref","first-page":"e32144","DOI":"10.1371\/journal.pone.0032144","article-title":"Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa","volume":"7","author":"Levison","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180626050757_CIT0034","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1093\/jac\/dks310","article-title":"Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting","volume":"67","author":"Maiga","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180626050757_CIT0035","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1089\/aid.2011.0352","article-title":"Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda","volume":"28","author":"Reynolds","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20180626050757_CIT0036","first-page":"769627","article-title":"Protease inhibitor resistance is uncommon in HIV-1 subtype C infected patients on failing second-line lopinavir\/r-containing antiretroviral therapy in South Africa","volume":"2011","author":"Wallis","year":"2011","journal-title":"AIDS Res Treat"},{"key":"key\n\t\t\t\t20180626050757_CIT0037","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3851\/IMP3005","article-title":"HIV drug resistance mutations among patients failing second-line antiretroviral therapy in Rwanda","volume":"21","author":"Ndahimana","year":"2016","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180626050757_CIT0038","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1097\/QAD.0000000000001500","article-title":"Emergence of untreatable, multidrug-resistant HIV-1 in patients failing second-line therapy in Kenya","volume":"31","author":"Inzaule","year":"2017","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180626050757_CIT0039","article-title":"Cross-sectional assessment of virological failure, drug resistance and third-line regimen requirements among patients receiving second-line ART in 3 large HIV programmes in Kenya, Malawi and Mozambique","volume":"19","author":"Schramm","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"key\n\t\t\t\t20180626050757_CIT0040","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1186\/s12879-015-1270-8","article-title":"Outcome of patients on second line antiretroviral therapy under programmatic condition in India","volume":"15","author":"Chakravarty","year":"2015","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20180626050757_CIT0041","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1758-2652-14-14","article-title":"High efficacy of lopinavir\/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER\/Calmette Hospital in Phnom Penh, Cambodia","volume":"14","author":"Ferradini","year":"2011","journal-title":"J Int AIDS Soc"},{"key":"key\n\t\t\t\t20180626050757_CIT0042","doi-asserted-by":"crossref","first-page":"e0120705","DOI":"10.1371\/journal.pone.0120705","article-title":"Week 120 efficacy of tenofovir, lamivudine and lopinavir\/r-based second-line antiretroviral therapy in treatment-experienced HIV patients","volume":"10","author":"Han","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180626050757_CIT0043","doi-asserted-by":"crossref","first-page":"8528","DOI":"10.1038\/srep08528","article-title":"Efficacy and biological safety of lopinavir\/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials","volume":"5","author":"Huang","year":"2015","journal-title":"Sci Rep"},{"key":"key\n\t\t\t\t20180626050757_CIT0044","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/cid\/civ556","article-title":"Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: a systematic review and meta-analysis","volume":"61","author":"Boender","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180626050757_CIT0045","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/S2352-3018(17)30087-5","article-title":"Resistance matters in EARNEST","volume":"4","author":"Maartens","year":"2017","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180626050757_CIT0046","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1093\/jac\/dkw218","article-title":"Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa","volume":"71","author":"Boender","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180626050757_CIT0047","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1089\/aid.2016.0010","article-title":"Short communication: high viral load and multidrug resistance due to late switch to second-line regimens could be a major obstacle to reach the 90-90-90 UNAIDS objectives in Sub-Saharan Africa","volume":"32","author":"Guichet","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20180626050757_CIT0048","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/QAI.0b013e318227fc34","article-title":"Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa","volume":"58","author":"Sigaloff","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180626050757_CIT0049","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3851\/IMP2010","article-title":"Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients","volume":"17","author":"Barth","year":"2012","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180626050757_CIT0050","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/cid\/cis254","article-title":"Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies","volume":"54","author":"Hamers","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180626050757_CIT0051","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1089\/aid.2015.0331","article-title":"Antiretroviral resistance after first-line antiretroviral therapy failure in diverse HIV-1 subtypes in the SECOND-LINE Study","volume":"32","author":"Lam","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20180626050757_CIT0052","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1086\/496892","article-title":"Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection","volume":"192","author":"Deeks","year":"2005","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180626050757_CIT0053","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1086\/430709","article-title":"Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection","volume":"41","author":"Campbell","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180626050757_CIT0054","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1016\/S2352-3018(17)30112-1","article-title":"Second-line antiretroviral therapy: so much to be done","volume":"4","author":"Assefa","year":"2017","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180626050757_CIT0055","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/tmi.12741","article-title":"Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa","volume":"21","author":"Fox","year":"2016","journal-title":"Trop Med Int Health"},{"key":"key\n\t\t\t\t20180626050757_CIT0056","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S2352-3018(14)00003-4","article-title":"Interventions to promote adherence to antiretroviral therapy in Africa: a network meta-analysis","volume":"1","author":"Mills","year":"2014","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180626050757_CIT0057","first-page":"003","article-title":"HIV-1 protease inhibitors resistance profiles in patients with virological failure on LPV\/r-based 2nd line regimen in Cambodia","volume":"S5","author":"Nerrienet","year":"2012","journal-title":"J AIDS Clin Res"},{"key":"key\n\t\t\t\t20180626050757_CIT0058","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/jac\/dkv385","article-title":"High prevalence of PI resistance in patients failing second-line ART in Vietnam","volume":"71","author":"Thao","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180626050757_CIT0059","article-title":"Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study","author":"Hermans","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180626050757_CIT0060","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S1473-3099(16)30469-8","article-title":"Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study","volume":"17","author":"Gregson","year":"2017","journal-title":"Lancet Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/66\/12\/1846\/25084480\/cix1108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T23:17:28Z","timestamp":1751152648000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/66\/12\/1846\/4767830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,20]]},"references-count":60,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12,20]]},"published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cix1108","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6,15]]},"published":{"date-parts":[[2017,12,20]]}}}